文献速递淋巴瘤

高代谢肿瘤体积与大B细胞淋巴瘤患者阿基仑赛疗效降低相关

High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma.
PubMed 文献 · Blood Adv · 2020-01-01

回顾性研究纳入96例接受阿基仑赛治疗的复发/难治性大B细胞淋巴瘤患者,基于基线PET的代谢肿瘤体积中位数147.5 mL分组,发现低代谢肿瘤体积组总生存和无进展生存均更优,结论在第二队列48例中验证。

要点

  • 基线代谢肿瘤体积与阿基仑赛治疗后的总生存和无进展生存相关。
  • 第一队列低代谢肿瘤体积组总生存HR 0.25(95%CI 0.10-0.66),无进展生存HR 0.40(95%CI 0.18-0.89)。
  • 第二队列验证低代谢肿瘤体积组总生存HR 0.14(95%CI 0.05-0.42),无进展生存HR 0.29(95%CI 0.12-0.69)。

核心结论

  • 基线代谢肿瘤体积与接受阿基仑赛治疗的大B细胞淋巴瘤患者的总生存和无进展生存相关。

研究设计与样本

  • 回顾性研究,两个队列共96例复发/难治性大B细胞淋巴瘤患者,接受阿基仑赛治疗。
  • 通过商用软件手工计算基线正电子发射断层扫描的代谢肿瘤体积,第一队列48例以中位数147.5 mL为界分为高、低代谢肿瘤体积组。
  • 第二队列48例用于验证结果。

主要发现

  • 第一队列低代谢肿瘤体积组总生存显著优于高代谢肿瘤体积组(HR 0.25;95%CI 0.10-0.66),无进展生存也显著更优(HR 0.40;95%CI 0.18-0.89)。
  • 第二队列验证低代谢肿瘤体积组总生存显著更优(HR 0.14;95%CI 0.05-0.42),无进展生存也显著更优(HR 0.29;95%CI 0.12-0.69)。
  • 第一队列存活者中位随访24.98个月(范围10.59-51.02个月),第二队列存活者中位随访12.03个月(范围0.89-25.74个月)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

High metabolic tumor volume (MTV) predicts worse outcomes in lymphoma treated with chemotherapy. However, it is unknown if this holds for patients treated with axicabtagene ciloleucel (axi-cel), an anti-CD19 targeted chimeric antigen receptor T-cell therapy. The primary objective of this retrospective study was to investigate the relationship between MTV and survival (overall survival [OS] and progression-free survival [PFS]) in patients with relapsed/refractory large B-cell lymphoma (LBCL) treated with axi-cel. Secondary objectives included finding the association of MTV with response rates and toxicity. The MTV values on baseline positron emission tomography of 96 patients were calculated via manual methodology using commercial software. Based on a median MTV cutoff value of 147.5 mL in the first cohort (n = 48), patients were divided into high and low MTV groups. Median follow-up for survivors was 24.98 months (range, 10.59-51.02 months). Patients with low MTV had significantly superior OS (hazard ratio [HR], 0.25; 95% confidence interval [CI], 0.10-0.66) and PFS (HR, 0.40; 95% CI, 0.18-0.89). Results were successfully validated in a second cohort of 48 patients with a median follow-up for survivors of 12.03 months (range, 0.89-25.74 months). Patients with low MTV were found to have superior OS (HR, 0.14; 95% CI, 0.05-0.42) and PFS (HR, 0.29; 95% CI, 0.12-0.69). In conclusion, baseline MTV is associated with OS and PFS in axi-cel recipients with LBCL.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Dean EA, Mhaskar RS, Lu H, et al. High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020. PMID: 32702097. doi:10.1182/bloodadvances.2020001900

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。